Save time and get answers to complex questions with AI chat
Drugpatentwatch trametinib?Guselkumab loss of exclusitivy?Dabrafenib patent expiration?When will generic fiasap insulin be available?Mebendazole ingredients?
See the DrugPatentWatch profile for exparel
Timeline of Pacira BioSciences' EXPAREL Generic Drug Application Filings in 2025 The U.S. Food and Drug Administration (FDA) approval for generic versions of EXPAREL, a non-opioid analgesic, is expected to be a contentious issue in 2025 [1]. EXPAREL, developed by Pacira BioSciences, is the first and only FDA-approved, long-acting local analgesic for postsurgical pain. When does exclusivity expire for EXPAREL in 2025? Pacira BioSciences' patent for EXPAREL, which was approved in 2010, is set to expire in 2029 [2]. However, the exclusivity for the drug will likely expire earlier, as generic manufacturers can file an ANDA (Abbreviated New Drug Application) with the FDA 180 days before the patent expires. How many generic drug applications for EXPAREL can be expected in 2025? As early as 2023, several generic manufacturers, such as Hikma Pharmaceuticals and Sandoz, have filed ANDAs with the FDA for the generic version of EXPAREL [3]. In 2025, other manufacturers, like Teva Pharmaceuticals and Mylan, will likely follow suit. What are the risks associated with generic versions of EXPAREL in 2025? Generic manufacturers may face patent challenges and litigation from Pacira BioSciences, which could delay the entry of generic versions into the market [4]. Moreover, the FDA will need to ensure that any generic versions of EXPAREL meet the same standards for safety and efficacy as the original drug. Will biosimilars be able to enter the market before Pacira's patent expires? Pacira's patent for EXPAREL prevents biosimilars from entering the market until 2029 [2]. While some biosimilars may file for approval, they will not be able to enter the market until the patent expires or is challenged. In conclusion, while some generic manufacturers may file ANDAs for the generic version of EXPAREL in 2025, the exclusivity for the drug will likely expire earlier. Pacira will likely face patent challenges and litigation from generic manufacturers, and the FDA will need to ensure that any generic versions meet the same standards for safety and efficacy. Sources: [1] DrugPatentWatch.com - https://drugpatentwatch.com/ [2] U.S. Food and Drug Administration - EXPAREL Label [3] Hikma Pharmaceuticals - ANDA Filings [4] Law360 - Pacira BioSciences Wins Patent Infringement Suit
Other Questions About Exparel :